《股市簡訊》中國康哲藥業漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理

路透中文

2025/12/12

《股市簡訊》中國<a href="https://laohu8.com/S/00867">康哲藥業</a>漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理

* 中國康哲藥業0867.HK周五早盤漲幅擴大至3.8%。

* 該公司此前公告稱，注射用洛貝米柳新藥上市許可申請獲得中國國家藥品監督管理局受理，產品為一種擬用於急性缺血性卒中的腦細胞保護劑。該藥物由南京寧丹新藥研發，康哲藥業在2023年獲得產品在中國大陸、香港、澳門的獨家推廣權。

* 康哲藥業今年迄今勁漲71.7%，同期恒生指數.HSI上揚28.3%。

* 恒生綜合行業指數 - 醫療保健業.HSCIH盤中一度跌0.4%。（完）

更多股市簡訊請點選CN-CMN-HOT

(發稿徐凱文；審校張喜良)

((kaiwen.xu@thomsonreuters.com))

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2590250915"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590250915\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590250915?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-12 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590250915","market":"hk","top_or_hot":-1,"title":"《股市簡訊》中國康哲藥業漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市簡訊》中國<a href=\"https://laohu8.com/S/00867\">康哲藥業</a>漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理</title></head><body><p>* 中國康哲藥業<span>0867.HK</span>周五早盤漲幅擴大至3.8%。</p><p>* 該公司此前公告稱，注射用洛貝米柳新藥上市許可申請獲得中國國家藥品監督管理局受理，產品為一種擬用於急性缺血性卒中的腦細胞保護劑。該藥物由南京寧丹新藥研發，康哲藥業在2023年獲得產品在中國大陸、香港、澳門的獨家推廣權。</p><p>* 康哲藥業今年迄今勁漲71.7%，同期恒生指數<span>.HSI</span>上揚28.3%。</p><p>* 恒生綜合行業指數 - 醫療保健業<span>.HSCIH</span>盤中一度跌0.4%。（完）</p><p>更多股市簡訊請點選<span>CN-CMN-HOT</span></p><p> (發稿 徐凱文；審校 張喜良)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市簡訊》中國康哲藥業漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市簡訊》中國康哲藥業漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2025-12-12 10:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市簡訊》中國<a href=\"https://laohu8.com/S/00867\">康哲藥業</a>漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理</title></head><body><p>* 中國康哲藥業<span>0867.HK</span>周五早盤漲幅擴大至3.8%。</p><p>* 該公司此前公告稱，注射用洛貝米柳新藥上市許可申請獲得中國國家藥品監督管理局受理，產品為一種擬用於急性缺血性卒中的腦細胞保護劑。該藥物由南京寧丹新藥研發，康哲藥業在2023年獲得產品在中國大陸、香港、澳門的獨家推廣權。</p><p>* 康哲藥業今年迄今勁漲71.7%，同期恒生指數<span>.HSI</span>上揚28.3%。</p><p>* 恒生綜合行業指數 - 醫療保健業<span>.HSCIH</span>盤中一度跌0.4%。（完）</p><p>更多股市簡訊請點選<span>CN-CMN-HOT</span></p><p> (發稿 徐凱文；審校 張喜良)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BMCWC346.EUR","symbol_name":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4S3XI03Q:1","article_id":"2590250915","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590250915","pubTimestamp":1765504877,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市簡訊》中國康哲藥業漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理* 中國康哲藥業0867.HK周五早盤漲幅擴大至3.8%。* 該公司此前公告稱，注射用洛貝米柳新藥上市許可申請獲得中國國家藥品監督管理局受理，產品為一種擬用於急性缺血性卒中的腦細胞保護劑。該藥物由南京寧丹新藥研發，康哲藥業在2023年獲得產品在中國大陸、香港、澳門的獨家推廣權。* 康哲藥業今年迄今勁漲71.7%，同期恒生指數.HSI上揚28.3%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK1593":"医美概念股","BK1191":"制药","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","00867":"康哲药业","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC"},"translate_title":"\"Stock Market Newsletter\" China CMS Pharmaceutical rose 3.8%, and the application for the marketing of the introduced stroke drug was accepted by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":0.9},"content_text":"《股市簡訊》中國康哲藥業漲3.8%，引進的卒中藥物上市申請獲國家藥監局受理* 中國康哲藥業0867.HK周五早盤漲幅擴大至3.8%。* 該公司此前公告稱，注射用洛貝米柳新藥上市許可申請獲得中國國家藥品監督管理局受理，產品為一種擬用於急性缺血性卒中的腦細胞保護劑。該藥物由南京寧丹新藥研發，康哲藥業在2023年獲得產品在中國大陸、香港、澳門的獨家推廣權。* 康哲藥業今年迄今勁漲71.7%，同期恒生指數.HSI上揚28.3%。* 恒生綜合行業指數 - 醫療保健業.HSCIH盤中一度跌0.4%。（完）更多股市簡訊請點選CN-CMN-HOT (發稿 徐凱文；審校 張喜良) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}